Iowanews Headlines

Acute Coronary Syndrome Market Insights

The Acute Coronary Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Coronary Syndrome pipeline products will significantly revolutionize the Acute Coronary Syndrome market dynamics.

DelveInsight’s “Acute Coronary Syndrome Market Insight, Epidemiology And Market Forecast – 2034″ report offers an in-depth understanding of the Acute Coronary Syndrome, historical and forecasted epidemiology as well as the Acute Coronary Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Acute Coronary Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Acute Coronary Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Visit Acute Coronary Syndrome Market Insights

Some of the key facts of the Acute Coronary Syndrome Market Report:

• Acute Coronary Syndrome market size was highest in the United States among the 7MM countries

• In February 2025, Idorsia and Viatris Revise Global Collaboration Agreement for Selatogrel and Cenerimod.

• The VESALIUS-CV Phase III cardiovascular outcomes study of REPATHA is currently underway, focusing on patients at high cardiovascular risk who have no history of myocardial infarction or stroke.

• Acute Coronary Syndrome Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra and others.

• Acute Coronary Syndrome Therapies: REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), CABPIRIN (aspirin/vonoprazan fumarate), SIGMART (nicorandil injection), INSPRA (eplerenone), PLAVIX (clopidogrel bisulfate), BRILIQUE (ticagrelor), BRILINTA (ticagrelor), EFFIENT (prasugrel), ATACAND (candesartan), DIOVAN (valsartan), VASCEPA (icosapent ethyl), Selatogrel (ACT-246475), FARXIGA/FORXIGA (dapagliflozin), FDY-5301, and Others

Acute Coronary Syndrome Overview

Acute Coronary Syndrome is a medical emergency that encompasses a group of conditions caused by sudden, reduced blood flow to the heart muscle due to partial or complete blockage of a coronary artery. This blockage, often resulting from a ruptured atherosclerotic plaque and subsequent blood clot formation, leads to insufficient oxygen supply to the heart, causing symptoms such as chest pain or pressure, shortness of breath, dizziness, and sometimes atypical signs especially in women, older adults, and people with diabetes. Acute Coronary Syndrome includes unstable angina and heart attacks classified as ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI). Immediate treatment is critical to restore blood flow and prevent irreversible heart damage or sudden cardiac death.

Acute Coronary Syndrome Market

The dynamics of the Acute Coronary Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2025-2034.

Acute Coronary Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Coronary Syndrome Epidemiology Segmentation:

The Acute Coronary Syndrome market report offers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Acute Coronary Syndrome

• Type-specific Incidence of Acute Coronary Syndrome

• Type-specific Incidence of AMI

• Gender-specific Incidence of Acute Coronary Syndrome

Download the report to understand which factors are driving Acute Coronary Syndrome epidemiology trends @ Acute Coronary Syndrome Epidemiological Insights

Acute Coronary Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Coronary Syndrome market or expected to get launched during the study period. The analysis covers Acute Coronary Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Coronary Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Acute Coronary Syndrome treatment, visit @ Acute Coronary Syndrome Medications

Acute Coronary Syndrome Therapies and Key Companies

• LODOCO (colchicine): AGEPHA Pharma

• REPATHA (evolocumab): Amgen

• PRALUENT (alirocumab): Regeneron and Sanofi

• REPATHA (evolocumab): Amgen

• ZONTIVITY (vorapaxar): Merck

• INSPRA (eplerenone): Pfizer

• LOVENOX (enoxaparin sodium): Sanofi

• FDY-5301: Faraday Pharmaceuticals

• Dutogliptin: Recardio

• FARXIGA/FORXIGA (dapagliflozin): AstraZeneca

• FDY-5301: Faraday Pharmaceuticals

• Ziltivekimab: Novo Nordisk

• Milvexian: Bristol Myers Squibb and Johnson & Johnson

• Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche

• Vicagrel: Jiangsu Vcare PharmaTech

• KAND567: Kancera

• ProtheraCytes: CellProthera and BioCardia

• MPC-25-IC: Mesoblast

Acute Coronary Syndrome Market Drivers

• High global burden of cardiovascular disease, keeping ACS a major cause of morbidity and mortality worldwide.

• Rising prevalence of risk factors such as hypertension, diabetes, obesity, dyslipidemia, and sedentary lifestyles.

• Aging population, increasing the pool of patients vulnerable to ACS events.

• Advancements in diagnostic technologies, including high-sensitivity troponin assays and rapid imaging tools enabling early detection.

• Improved interventional cardiology techniques, such as next-generation stents, drug-eluting technologies, and minimally invasive procedures.

• Growing adoption of evidence-based guidelines promoting early intervention and optimized medical therapy.

• Emergence of novel therapeutics, including PCSK9 inhibitors, antithrombotics, and inflammation-targeting agents.

• Increased healthcare spending and access to emergency cardiac care, especially in developing regions.

• Expansion of cardiac rehabilitation programs, boosting demand for long-term management therapies.

• Ongoing research and strong R&D pipelines focused on reducing recurrent events and improving outcomes.

Acute Coronary Syndrome Market Barriers

• High treatment costs, especially for advanced antithrombotics, biologics, and interventional procedures.

• Delayed diagnosis in resource-limited settings, leading to missed early treatment windows.

• Variability in access to PCI-capable centers, particularly in low- and middle-income countries.

• Safety concerns with long-term antithrombotic therapy, including elevated bleeding risk.

• Stringent regulatory requirements for cardiovascular drug approval due to safety sensitivity.

• Slow adoption of new therapies stemming from physician preference for established standard-of-care treatments.

• Complexity and high cost of cardiovascular clinical trials, which require large sample sizes and long follow-up.

• Heterogeneity of patient populations, complicating trial design and personalized treatment strategies.

• Payer pressure and reimbursement challenges, especially for high-cost therapies lacking clear superiority.

• Limited patient adherence to chronic post-ACS medications, reducing real-world effectiveness.

Scope of the Acute Coronary Syndrome Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acute Coronary Syndrome Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra

• Key Acute Coronary Syndrome Therapies: REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), CABPIRIN (aspirin/vonoprazan fumarate), SIGMART (nicorandil injection), INSPRA (eplerenone), PLAVIX (clopidogrel bisulfate), BRILIQUE (ticagrelor), BRILINTA (ticagrelor), EFFIENT (prasugrel), ATACAND (candesartan), DIOVAN (valsartan), VASCEPA (icosapent ethyl), Selatogrel (ACT-246475), FARXIGA/FORXIGA (dapagliflozin), FDY-5301, and Others

• Acute Coronary Syndrome Therapeutic Assessment: Acute Coronary Syndrome current marketed and Acute Coronary Syndrome emerging therapies

• Acute Coronary Syndrome Market Dynamics: Acute Coronary Syndrome market drivers and Acute Coronary Syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Acute Coronary Syndrome Unmet Needs, KOL’s views, Analyst’s views, Acute Coronary Syndrome Market Access and Reimbursement

Discover more about therapies set to grab major Acute Coronary Syndrome market share @ Acute Coronary Syndrome Treatment Landscape

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Acute Coronary Syndrome Market Overview at a Glance

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Acute Coronary Syndrome Background and Overview

8. Acute Coronary Syndrome Treatment

9. Acute Coronary Syndrome Epidemiology and Patient Population in the 7MM

10. Acute Coronary Syndrome Patient Journey

11. Acute Coronary Syndrome Marketed Drug

12. Acute Coronary Syndrome Emerging Drugs

13. Acute Coronary Syndrome: 7MM Analysis

14. Unmet needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services